| Trial ID: | L4210 |
| Source ID: | NCT01542424
|
| Associated Drug: |
Biphasic Insulin Aspart 30
|
| Title: |
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: biphasic insulin aspart 30|DRUG: insulin detemir
|
| Outcome Measures: |
Primary: HbA1c (glycosylated haemoglobin) | Secondary: Percentage of subjects reaching HbA1c target of maximum 7.0%|Postprandial plasma glucose (PPG)|Fasting plasma glucose (FPG)|Change in body weight|Incidence of adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1889
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2006-03
|
| Completion Date: |
2006-12
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-31
|
| Locations: |
Novo Nordisk Investigational Site, Skopje, MK-1000, Macedonia, The Former Yugoslav Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT01542424
|
